Imfinzi (durvalumab) - AstraZeneca
Tecentriq (atezolizumab) - Roche
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Hetronifly (serplulimab) - Shanghai Henlius Biotech
Keytruda (pembrolizumab) - Merck (MSD)
Loqtorzi (toripalimab-tpzi) - Shanghai Junshi Bioscience, Coherus Oncology
https://cattendee.abstractsonline.com/meeting/21487/presentation/3271
 
A. Rajbhoj1; K. Joshi2; P. Kalaskar2; U. Maheshwari2; D. Morzaria2; A. Joshi2; V. Maniar3; C. Pethe4; B. Shah5; A. Kakroo5; S. Bhosale2; R. Dave1; T. Sethjiwala6; S. Jagiasi2; M. Randive7; A. Tongaonkar2; N. Bayas2; A. Pathan1; R. Khwaja2; T. Patil1; R. Wategaonkar1
 
Jul 31, 2026
 
Prev Next